Simris Group AB (“Simris” or the “Company”) announces that discussions with Immunrise Biocontrol France SAS (“Immunrise”) continue, on a non-exclusive basis, beyond the deadline of March 1, 2026 and with both parties working towards the completion of the transaction.
Simris and Immunrise entered into a Memorandum of Understanding (“MoU”) on Jan 19, 2026 with the objective that Immurise would submit a binding offer for Simris’ production facility at Hammenhög, Sweden by March 1, 2026. Despite the period of exclusivity period expiring, negotiations continue on a non-exclusive basis and with both parties committed to completing the transaction as soon as possible.